{
    "clinical_study": {
        "@rank": "72119", 
        "acronym": "ADAPT", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "nab-Paclitaxel + gemcitabine"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "nab-Paclitaxel + carboplatin"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either\n      carboplatin or gemcitabine for patients with triple negative breast cancer."
        }, 
        "brief_title": "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Female patients, age at diagnosis 18 - 75 years\n\n          -  Histologically confirmed unilateral primary invasive carcinoma of the breast\n\n          -  Clinical T1 - T4 (except inflammatory breast cancer)\n\n          -  All clinical N (cN)\n\n          -  No clinical evidence for distant metastasis (M0)\n\n          -  Known HR status and HER2 status (local pathology)\n\n          -  Tumor block available for central pathology review\n\n          -  Performance Status ECOG < 1 or KI > 80 %\n\n          -  Negative pregnancy test (urine or serum) within 7 days prior to start of induction\n             treatment in premenopausal patients\n\n          -  Written informed consent prior to beginning specific protocol procedures, including\n             expected cooperation of the patients for the treatment and follow-up, must be\n             obtained and documented according to the local regulatory requirements\n\n          -  The patient must be accessible for treatment and follow-up\n\n        Additional Inclusion Criteria for patients receiving chemotherapy:\n\n          -  Laboratory requirements for patients receiving neoadjuvant chemotherapy (within 14\n             days prior to induction treatment):\n\n               -  Leucocytes >= 3.5 10^9/L\n\n               -  Platelets >= 100 10^9/L\n\n               -  Hemoglobin >= 10 g/dL\n\n               -  Total bilirubin <= 1 x ULN\n\n               -  ASAT (SGOT) and ALAT (SGPT) <= 2.5 x UNL\n\n               -  Creatinine <= 175 \u00b5mol/L (2 mg/dl)\n\n          -  LVEF within normal limits of each institution measured by echocardiography and normal\n             ECG (within 42 days prior to induction treatment)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity reaction to the compounds or incorporated substances\n\n          -  Prior malignancy with a disease-free survival of < 10 years, except curatively\n             treated basalioma of the skin or pTis of the cervix uteri\n\n          -  Non-operable breast cancer including inflammatory breast cancer\n\n          -  Previous or concurrent treatment with cytotoxic agents for any reason after\n             consultation with the sponsor\n\n          -  Concurrent treatment with other experimental drugs. Participation in another\n             interventional clinical trial with or without any investigational not marketed drug\n             within 30 days prior to study entry\n\n          -  Male breast cancer\n\n          -  Concurrent pregnancy; patients of childbearing potential must implement a highly\n             effective (less than 1% failure rate) non-hormonal contraceptive measures during the\n             study treatment\n\n          -  Breast feeding woman\n\n          -  Sequential breast cancer\n\n          -  Reasons indicating risk of poor compliance\n\n          -  Patients not able to consent\n\n        Additional Exclusion Criteria for patients receiving chemotherapy:\n\n          -  Known polyneuropathy \u2265 grade 2\n\n          -  Severe and relevant co-morbidity that would interact with the application of\n             cytotoxic agents or the participation in the study including acute cystitis and\n             ischuria and chronic kidney disease\n\n          -  Uncompensated cardiac function\n\n          -  Inadequate organ function including:\n\n               -  Leucocytes < 3.5 x 10^9/l\n\n               -  Platelets < 100 x 10^9/l\n\n               -  Bilirubin above normal limits\n\n               -  Alkaline phosphatase > 5 x UNL\n\n               -  ASAT and/or ALAT associated with AP > 2.5 x UNL"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "336", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815242", 
            "org_study_id": "WSG-AM06 / ADAPT TN"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "nab-Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "ulrike.nitz@wsg-online.com", 
                "last_name": "Ulrike Nitz, Prof. Dr.", 
                "phone": "+492161981", 
                "phone_ext": "2330"
            }, 
            "facility": {
                "address": {
                    "city": "Moenchengladbach", 
                    "country": "Germany", 
                    "zip": "41061"
                }, 
                "name": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, M\u00f6nchengladbach, Germany"
            }, 
            "investigator": {
                "last_name": "Raquel von Schumann, Dr. med.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer", 
        "overall_contact": {
            "email": "daniel.hofmann@wsg-online.com", 
            "last_name": "Daniel Hofmann, M. Sc.", 
            "phone": "+49216156623", 
            "phone_ext": "17"
        }, 
        "overall_official": [
            {
                "affiliation": "Breast Center of the University of Munich (LMU), Universit\u00e4tsfrauenklinik Gro\u00dfhadern, Munich, Germany", 
                "last_name": "Nadia Harbeck, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, M\u00f6nchengladbach, Germany", 
                "last_name": "Ulrike Nitz, Prof. Dr.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "pCR will be measured after 12 weeks of randomized treatment.", 
                "measure": "Comparison: pCR in nab-paclitaxel/carboplatin vs. nab-paclitaxel/gemcitabine", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of therapy"
            }, 
            {
                "description": "pCR will be measured after 12 weeks of randomized treatment.", 
                "measure": "Comparison: pCR in responders vs. non-responders", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of therapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "West German Study Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "West German Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}